These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 6860057)

  • 1. Hearing loss and erythromycin pharmacokinetics in a patient receiving hemodialysis.
    Kroboth PD; McNeil MA; Kreeger A; Dominguez J; Rault R
    Arch Intern Med; 1983 Jun; 143(6):1263-5. PubMed ID: 6860057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinically significant hearing loss in renal allograft recipients treated with intravenous erythromycin.
    Vasquez EM; Maddux MS; Sanchez J; Pollak R
    Arch Intern Med; 1993 Apr; 153(7):879-82. PubMed ID: 8466379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in erythromycin pharmacokinetics induced by renal failure.
    Kanfer A; Stamatakis G; Torlotin JC; Fredj G; Kenouch S; Méry JP
    Clin Nephrol; 1987 Mar; 27(3):147-50. PubMed ID: 3494560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erythromycin ototoxicity and acute psychotic reaction in cancer patients with hepatic dysfunction.
    Umstead GS; Neumann KH
    Arch Intern Med; 1986 May; 146(5):897-9. PubMed ID: 3963982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ototoxicity of erythromycin in peritoneal dialysis patients.
    Taylor R; Schofield IS; Ramos JM; Bint AJ; Ward MK
    Lancet; 1981 Oct; 2(8252):935-6. PubMed ID: 6117714
    [No Abstract]   [Full Text] [Related]  

  • 6. [Ototoxic potential of erythromycin].
    Demaldent JE; Rolland A; Mongrolle Y
    Ann Otolaryngol Chir Cervicofac; 1984; 101(8):643-7. PubMed ID: 6534259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hearing loss after erythromycin therapy].
    Lind O; Harthug S
    Tidsskr Nor Laegeforen; 1993 Sep; 113(22):2810-1. PubMed ID: 8211901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of intravenous erythromycin lactobionate.
    Parsons RL; David JA; Raymond K; Stamp SM
    J Int Med Res; 1980; 8 Suppl 2():15-23. PubMed ID: 6968696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erythromycin associated hearing loss in a patient with prior cis-platinum induced ototoxicity.
    Wallach PM; Love SR; Fiorica JV; Hoffman MS; Flannery MT
    J Fla Med Assoc; 1992 Dec; 79(12):821-2. PubMed ID: 1474367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Amikacin-induced hearing loss in patients treated with repeated hemodialysis].
    Niemierko J; Rutkowski B
    Pol Tyg Lek; 1984 Nov; 39(45):1477-8. PubMed ID: 6514625
    [No Abstract]   [Full Text] [Related]  

  • 11. [Reversible hearing loss and erythromycin].
    Rydberg J
    Lakartidningen; 1984 Mar; 81(13):1308. PubMed ID: 6708672
    [No Abstract]   [Full Text] [Related]  

  • 12. [Ototoxicity of erythromycin].
    van Marion WF; van der Meer JW; Kalff MW; Schicht SM; Baarsma EA
    Ned Tijdschr Geneeskd; 1979 Dec; 123(48):2066-8. PubMed ID: 514397
    [No Abstract]   [Full Text] [Related]  

  • 13. Reversible sensorineural hearing loss with intravenous erythromycin lactobionate.
    Karmody CS; Weinstein L
    Ann Otol Rhinol Laryngol; 1977; 86(1 Pt 1):9-11. PubMed ID: 835977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of vancomycin when administered during high flux hemodialysis.
    Foote EF; Dreitlein WB; Steward CA; Kapoian T; Walker JA; Sherman RA
    Clin Nephrol; 1998 Jul; 50(1):51-5. PubMed ID: 9710347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacodynamics of erythromycin lactobionate during tonsillectomy in children].
    Leuthardt R; Trümpi B; Morger R
    Schweiz Med Wochenschr; 1989 Oct; 119(40):1372-4. PubMed ID: 2799345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aminoglycosides in intermittent hemodialysis: pharmacokinetics with individual dosing.
    Dager WE; King JH
    Ann Pharmacother; 2006 Jan; 40(1):9-14. PubMed ID: 16332944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Erythromycin-induced hearing loss in a patient with Listeria monocytogenes meningo-ventriculitis].
    Moriyasu H; Oita J; Minematsu K; Yamaguchi T
    Rinsho Shinkeigaku; 1996 Sep; 36(9):1107-9. PubMed ID: 8976138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pharmacokinetics of two erythromycin esters in plasma and in saliva following oral administration in humans.
    Ducci M; Scalori V; del Tacca M; Soldani G; Bernardini C; Grothe E; Bertelli A
    Int J Clin Pharmacol Ther Toxicol; 1981 Nov; 19(11):494-7. PubMed ID: 7298242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of temsirolimus pharmacokinetics in patients with renal cell carcinoma not receiving dialysis and those receiving hemodialysis: a case series.
    Lunardi G; Armirotti A; Nicodemo M; Cavallini L; Damonte G; Vannozzi MO; Venturini M
    Clin Ther; 2009 Aug; 31(8):1812-9. PubMed ID: 19808140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erythromycin ototoxicity: prospective assessment with serum concentrations and audiograms in a study of patients with pneumonia.
    Swanson DJ; Sung RJ; Fine MJ; Orloff JJ; Chu SY; Yu VL
    Am J Med; 1992 Jan; 92(1):61-8. PubMed ID: 1731511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.